TAG:
clinical lab testing
2009’s Top Ten Lab Stories Reflect Some Good, Bad
By Robert Michel | From the Volume XVI No. 17 – December 14, 2009 Issue
CEO SUMMARY: As the closing year of the first decade of the new century and the new millennium, 2009 brought neither disruption nor upheaval to the majority of laboratories in the United States. Rather, it was marked by at least two themes. One was how public disclosure of problems with l…
The $1,000 Genome and Laboratory Testing
By R. Lewis Dark | From the Volume XVI No. 16 – November 23, 2009 Issue
IT WAS 1953 WHEN JAMES D. WATSON AND FRANCIS CRICK, working from X-ray data collected by Rosalind Franklin, described the double helix structure of the DNA molecule. That discovery inspired scientists to begin investigating the genetic basis of life. In the 56 years since Watson and Crick published …
$750 Million Lab Test Tax Proposed in Senate Bill
By Robert Michel | From the Volume XVI No. 13 – September 21, 2009 Issue
CEO SUMMARY: A bill that may be the U.S. Senate’s framework for reforming the U.S. healthcare system calls for a tax of $750 million per year to be paid by lab testing companies. The proposed bill also calls for a reduction in Medicare reimbursement for lab testing. One positiv…
Irish Labs Appeal to Keep Pap Smear Expertise
By Robert Michel | From the Volume XVI No. 12 – August 31, 2009 Issue
CEO SUMMARY: In Ireland, pathologists are asking the government to return enough Pap tests back to the country to support and sustain medical training programs in gynecologic cytology. It was 2008 when the Irish government outsourced all Pap testing to a U.S. lab company. That forced Irel…
Creative Destruction in Anatomic Pathology
By R. Lewis Dark | From the Volume XV No. 2 – February 11, 2008 Issue
PATHOLOGISTS MAY BE FAMILIAR with the economic theory of “creative destruction.” They are aware of how “creative destruction” is at work transforming and reshaping both the anatomic pathology marketplace and the clinical lab testing marketplace. Economist Joseph Schumpeter first used the ter…
Siemens Acquires Dade, Builds IVD Powerhouse
By Robert Michel | From the Volume XIV No. 11 – August 6, 2007 Issue
CEO SUMMARY: In just 15 months, Siemens AG has pulled out its checkbook three times to spend more than $14 billion to acquire major in vitro diagnostics (IVD) companies. When it closes the purchase of Dade Behring, Siemens will be in the first rank of global IVD manufacturers. It has also…
Global Laboratory Trends Dominated by Rising Costs and Labor Shortage
By Robert Michel | From the Volume XIV No. 9 – June 25, 2007 Issue
“The Web has transformed many industries and it’s clearly affected our industry. This trend will help raise the bar in quality and overall performance among laboratories and manufacturers.” —Jim Reid-Anderson Chairman, President, and CEO of Dade Behring…
How Local Path Groups Can Keep Patient Access
By Robert Michel | From the Volume XI No.13 – September 20, 2004 Issue
CEO SUMMARY: For pathology groups operating their own histology and cytology labs, a growing problem is access to patients covered by exclusive managed care contracts. In the Northeast, several persistent pathology group practices are using some effective business strategies to fight this…
Linking UroCor Indictments With Specialist Doc Pathology
By Robert Michel | From the Volume XI No. 10 – July 19, 2004 Issue
IS THE TIMING of the criminal indictments of three ex-UroCor executives going to be a fortuitous event for the anatomic pathology profession? I ask this question because the exploding trend of specialist physician groups internalizing anatomic pathology services was slated to be the…
National AP Firms Target Gastroenterology Groups
By Robert Michel | From the Volume XI No. 9 – June 28, 2004 Issue
CEO SUMMARY: It’s a trend as yet invisible to the radar screens of most pathology groups. A new crop of specialty AP companies is targeting gastroenterology. In the past 36 months, several have posted phenomenal growth in both specimen volume and revenue. The heightened competition for …
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized